ArticleFrontiers in nutrition2026
The relationship between triglyceride-glucose index, triglyceride-glucose-body mass index, and the severity of hepatic steatosis and liver fibrosis in patients with MASLD: a cross-sectional study.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinical Utility of the Triglyceride-Glucose Index in Assessing Hepatic Steatosis Severity Within the MASLD Spectrum.Diagnostics (Basel, Switzerland) · 2026Article
- Waist circumference partially mediates the non-linear association between TyHGB and MASLD in non-diabetic Japanese adults.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to investigate the relationship between the triglyceride-glucose (TyG) index and the triglyceride-glucose-body mass (TyG-BMI) index and the severity of hepatic steatosis and liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), providing more accurate metabolic indicators for non-invasive screening. Methods: A retrospective analysis was conducted on 7,035 subjects who completed Fibrotouch testing. Multivariate logistic regression analysis was used to assess the correlation between the TyG index and TyG-BMI index and the severity of hepatic steatosis (mild, moderate, severe) and hepatic fibrosis. Quartile grouping analysis and ROC curve assessment were also used to evaluate predictive performance. Results: After adjusting for potential confounding factors, both the TyG index and the TyG-BMI index were significantly positively correlated with the severity of MASLD (both Conclusions: The TyG-BMI index is a strong predictor of MASLD severity and liver fibrosis, with predictive performance superior to that of the traditional TyG index. It can serve as an effective tool for clinical screening of high-risk populations for MASLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.